Results 221 to 230 of about 699,599 (311)
Validation of a Composite Mortality End Point in a Large Clinicogenomic Real-World Database of Patients With Advanced Cancer. [PDF]
Kapilivsky J +7 more
europepmc +1 more source
ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin +3 more
wiley +1 more source
A Lightweight Hybrid Authentication and Key Agreement Protocol for Decentralized Device-to-Device Communication with Post-Quantum Confidentiality. [PDF]
Savón-Berenguer A +3 more
europepmc +1 more source
Abstract The development of renewable energy sources is important in order to achieve the United Nations Sustainable Development Goals (SDGs). Waste cooking oil (WCO) is a promising feedstock for biodiesel production through transesterification. Heterogeneous bifunctional catalysts offer a sustainable alternative to conventional homogeneous bases such ...
Frederick Jit Fook Phang +9 more
wiley +1 more source
The analysis of competing hypotheses and expert witness testimony: Counteracting adversarial allegiance in witness credibility assessments? [PDF]
Otzipka J, Volbert R.
europepmc +1 more source
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi +2 more
wiley +1 more source
Towards Protecting the Injured Party from Errors and Hallucinations of Artificial Intelligence: A Contemporary Legal Perspective. [PDF]
Abouhaiba N, Khouli SA, Khater M.
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source

